Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T63484
|
||||
| Former ID |
TTDR00008
|
||||
| Target Name |
Glucose-6-phosphate dehydrogenase
|
||||
| Gene Name |
G6PD
|
||||
| Synonyms |
G6PD
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Chronic obstructive pulmonary disease [ICD9: 490-492, 494-496; ICD10: J40-J44, J47] | ||||
| Rheumatoid arthritis [ICD9: 710-719, 714; ICD10: M05-M06] | |||||
| Function |
Catalyzesthe rate-limiting step of the oxidative pentose-phosphate pathway, which represents a route for the dissimilation of carbohydrates besides glycolysis. The main function of this enzyme is to provide reducing power (NADPH) and pentose phosphates for fatty acid and nucleic acid synthesis.
|
||||
| BioChemical Class |
Short-chain dehydrogenases reductases
|
||||
| Target Validation |
T63484
|
||||
| UniProt ID | |||||
| EC Number |
EC 1.1.1.49
|
||||
| Sequence |
MAEQVALSRTQVCGILREELFQGDAFHQSDTHIFIIMGASGDLAKKKIYPTIWWLFRDGL
LPENTFIVGYARSRLTVADIRKQSEPFFKATPEEKLKLEDFFARNSYVAGQYDDAASYQR LNSHMNALHLGSQANRLFYLALPPTVYEAVTKNIHESCMSQIGWNRIIVEKPFGRDLQSS DRLSNHISSLFREDQIYRIDHYLGKEMVQNLMVLRFANRIFGPIWNRDNIACVILTFKEP FGTEGRGGYFDEFGIIRDVMQNHLLQMLCLVAMEKPASTNSDDVRDEKVKVLKCISEVQA NNVVLGQYVGNPDGEGEATKGYLDDPTVPRGSTTATFAAVVLYVENERWDGVPFILRCGK ALNERKAEVRLQFHDVAGDIFHQQCKRNELVIRVQPNEAVYTKMMTKKPGMFFNPEESEL DLTYGNRYKNVKLPDAYERLILDVFCGSQMHFVRSDELREAWRIFTPLLHQIELEKPKPI PYIYGSRGPTEADELMKRVGFQYEGTYKWVNPHKL |
||||
| Drugs and Mode of Action | |||||
| Drug(s) | Prasterone | Drug Info | Approved | Chronic obstructive pulmonary disease | [1] |
| EPIANDROSTERONE | Drug Info | Phase 3 | Discovery agent | [2] | |
| CBF-BS2 | Drug Info | Discontinued in Phase 2 | Rheumatoid arthritis | [3] | |
| Inhibitor | 2'-Monophosphoadenosine 5'-Diphosphoribose | Drug Info | [4] | ||
| EPIANDROSTERONE | Drug Info | [5] | |||
| Hydroxyacetic Acid | Drug Info | [4] | |||
| Metazamide | Drug Info | [6] | |||
| Prasterone | Drug Info | [6] | |||
| Modulator | CBF-BS2 | Drug Info | [7] | ||
| Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
| TEP | EXP Info | ||||
| Pathways | |||||
| BioCyc Pathway | Pentose phosphate pathway | ||||
| Pentose phosphate pathway (oxidative branch) | |||||
| KEGG Pathway | Pentose phosphate pathway | ||||
| Glutathione metabolism | |||||
| Metabolic pathways | |||||
| Biosynthesis of antibiotics | |||||
| Carbon metabolism | |||||
| Central carbon metabolism in cancer | |||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| PathWhiz Pathway | Pentose Phosphate Pathway | ||||
| Warburg Effect | |||||
| Reactome | TP53 Regulates Metabolic Genes | ||||
| WikiPathways | Sulfation Biotransformation Reaction | ||||
| NRF2 pathway | |||||
| Nuclear Receptors Meta-Pathway | |||||
| Vitamin D Receptor Pathway | |||||
| miR-targeted genes in muscle cell - TarBase | |||||
| miR-targeted genes in lymphocytes - TarBase | |||||
| miR-targeted genes in leukocytes - TarBase | |||||
| miR-targeted genes in epithelium - TarBase | |||||
| Cori Cycle | |||||
| Metabolism of carbohydrates | |||||
| Pentose Phosphate Pathway | |||||
| Glutathione metabolism | |||||
| References | |||||
| REF 1 | Direct agonist/antagonist functions of dehydroepiandrosterone. Endocrinology. 2005 Nov;146(11):4568-76. Epub 2005 Jun 30. | ||||
| REF 2 | ClinicalTrials.gov (NCT02151006) Does Dehydro Epiandrosterone (DHEA) Improve Pregnancy Rate in Women Undergoing IVF/ICSI With Expected Poor Ovarian Response?. U.S. National Institutes of Health. | ||||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007279) | ||||
| REF 4 | How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | ||||
| REF 5 | Bioorg Med Chem. 2009 Mar 15;17(6):2483-9. Epub 2009 Feb 4.Inhibition of Trypanosoma brucei glucose-6-phosphate dehydrogenase by human steroids and their effects on the viability of cultured parasites. | ||||
| REF 6 | Glucose utilization and activity of glucose-6-phosphate dehydrogenase, isocitrate dehydrogenase and malate dehydrogenase in rat erythrocytes after treatment with tuberculostatic agents. Vopr Med Khim. 1986 Sep-Oct;32(5):32-5. | ||||
| REF 7 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007279) | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.